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Stem cells, owing to their ability to differentiate into specialized cells that can serve a 
particular function, have enormous potential in the field of regenerative medicine, wherein 
these stem cell-based therapies can be used to treat a wide range of diseases including 
diabetes, heart disease, and liver disease.[1] However, the realization of stem cell-based 
therapies in the clinic is severely hampered by our current inability to achieve the efficient 
delivery of genetic materials into target cells, which is required to specifically direct 
differentiation. In particular, with regard to stem cell-based regenerative medicine, it is vital 
to achieve: i) the highly efficient transfection of targeted cells; ii) biocompatibility, with an 
emphasis on maintaining a high cell viability without altering migratory and differentiation 
potential; and iii) non-invasive monitoring for the long-term evaluation of therapy.[2]
Currently, the use of virus-mediated delivery results in the highest delivery efficiency (80–
90%) for stem cells.[3] However, this method also has a number of harmful effects that limit 
its clinical applicability including potential cell toxicities, mutagenesis, and the induction of 
an immune response.[4] To this end, a significant amount of effort has been invested in the 
development of alternative non-viral delivery methods.[2c] In particular, recent studies have 
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demonstrated that magnetic nanoparticles (MNPs) possess a number of advantages that are 
especially attractive for application to stem cell research.[5] Typically, MNPs are composed 
of a magnetic core that can consist of metals or metal oxides,[6] metal alloys,[7] and more 
recently, doped metals.[8] These MNP cores can then be post-synthetically modified with a 
biocompatible material (e.g. SiO2, gold, polymer, etc) resulting in a core-shell structure.[9] 
In doing so, this shell can not only act as a hydrophilic layer but also as a platform for the 
surface functionalization of the MNPs.[10] As a result of its inherent magnetism, the 
properties of the shell, and the surface functionalization employed, MNPs can possess 
multifunctionalities including the delivery of nucleic acids such as plasmid DNA (pDNA) 
and short interfering RNA (siRNA), magnetically-facilitated delivery, cell targeting, and 
MRI contrast.[11] In particular, the synthesis of gold coated MNPs can provide a number of 
additional advantages such near-infrared (NIR) absorption,[12] photon scattering, and a 
relatively inert and facile surface that is amenable to further functionalization, while 
preserving the core magnetic properties.[13]
Herein, we describe the synthesis of well-defined magnetic core-shell nanoparticles 
[MCNPs], composed of a highly magnetic core surrounded by a thin uniform gold shell and 
their application for the delivery of genetic materials (siRNA and pDNA) into stem cells in a 
highly efficient, spatiotemporally controlled, and biocompatible manner (Figure 1). 
Moreover, we demonstrate the utility of the multifunctionalities that are provided by our 
MCNP system including magnetically-facilitated transfection and dark-field imaging. While 
numerous studies have previously utilized MNPs as MRI contrast agents and have shown 
the effectiveness of magnetically facilitated transfection in stem cells, the use of MCNPs to 
mediate the delivery of genetic materials to stem cells in a highly efficient and 
biocompatible manner remains to be assessed. To this end, as a proof-of-concept experiment 
for the genetic manipulation of stem cells using MCNPs and the accompanying 
differentiation studies, neural stem cells (NSCs) were chosen as they are known to be very 
sensitive to conventional exogenous lipid-based transfection reagents as well as difficult-to-
transfect.[2a] Specifically, we hypothesized that we could achieve a significantly higher 
transfection efficiency for genetic materials without compromising stem cell viability and 
biological functions (e.g. differentiation) using our MCNP-based magnetically-facilitated 
delivery. In addition, we hypothesized that the gold shell would provide additional 
advantages for stem cell-based therapies through the ability to perform dark field imaging, 
as this would be a simple method with which to confirm the presence of MCNPs within 
stem cells prior to transplantation or other studies.
For the formation of our MCNPs, we chose doped magnetic nanoparticles (ZnFe2O4) as our 
core, since these MNPs have been shown to have a significantly higher magnetic 
susceptibility and hence can afford improved magnetic properties at much lower 
concentrations when compared to conventional MNPs.[8] As such, we first synthesized these 
ZnFe2O4 NPs via the thermal decomposition of a mixture of metal precursors in the 
presence of oleic acid as a stabilizer, using a modified synthetic protocol that was previously 
reported.[8] These ZnFe2O4 NPs were then coated with a thin layer of Au by reducing 
hydrogen tetrachloroaurate hydrate (HAuCl4.3H2O) in a chloroform solution of oleylamine 
in the presence of ZnFe2O4 NPs, which resulted in the formation of non-water-soluble 
MCNPs (Figure 1A).[14] These non-water-soluble ZnFe2O4@Au nanoparticles were then 
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rendered water-soluble by exchanging their surface oleylamine moieties with 11-
mercaptoundecanoic acid (MUA).[15] Initial characterization was performed to confirm that 
the water-soluble MCNPs (Figure 1A) retained their magnetic properties (Figure 2D) and 
showed a distinct pink coloration, which resembles a gold colloidal solution (Figure 2E), 
due to the surface plasmon resonance (SPR) properties of the outer Au shell.
A detailed characterization of the as-synthesized MCNPs (ZnFe2O4@Au NPs) was then 
performed. First, transmission electron microscopy (TEM) analysis revealed that the overall 
diameter increased from 20 ± 1.2 nm (n=100) for the ZnFe2O4 MNPs (See supporting 
information, Figure S1) to 25 ± 2.7 nm (n=100) for the ZnFe2O4@Au NPs (Figure 2A). The 
lattice fringes in the Au shell can clearly be seen in the HRTEM (Figure 2B), and the 
interfringe spacing was measured to be 0.201 nm, which is the interplane distance of the 
(200) planes in the face centered cubic (fcc) Au. This indicates that the ZnFe2O4 
nanoparticles are indeed coated with a layer of crystalline Au (~2.5 nm). Furthermore, from 
the HRTEM images (Figure 2B), we observed a difference in the contrast between the 
darker ZnFe2O4 core and the lighter Au shell. It has been reported that this is attributed to 
the dominance of the mass contrast over the diffraction contrast, making Au appear lighter 
in spite of it having a higher electron density than Fe and Zn.[16] We also confirmed that the 
MCNPs were composed of Zn, Fe, and Au using Energy Dispersive X-Ray Spectroscopy 
(EDAX) analysis (Figure 2C). Finally, from the UV absorption data (Figure 2F), we clearly 
observed that the water-soluble MCNPs show a distinct absorption peak at 540 nm, owing to 
the SPR properties of the water-soluble Au nanostructures. As expected, this peak is not 
observed in both the core ZnFe2O4 MNPs and the non-water-soluble ZnFe2O4@Au NPs 
coated with oleylamine.
To prepare these aforementioned MCNP constructs for the delivery of functional genetic 
materials such as siRNAs or pDNAs, the water-soluble MCNPs were coated with a cationic 
polyamine-dendrimer that was previously developed by our group[17] (Figure 1A; See 
supporting information, Figure S2) to afford an overall positive charge to the MCNPs. This 
positive charge facilitated MCNP complexation with negatively charged siRNA or pDNA. 
In addition, the cationic polyamine-dendrimer has multiple primary amine groups and hence, 
once the MCNP constructs are internalized, it can act as a proton sponge in the endosomes, 
thereby aiding in subsequent endosomal escape of the complexes and protecting the cargo 
from the deleterious effects of the acidic microenvironment.[17] The hydrodynamic size of 
the final MCNP constructs was determined to be 70 ± 2 nm and their net surface charge was 
found to be +15 mV using dynamic light scattering (DLS) and zeta potential measurements, 
respectively (See supporting information, Figure S3). Additionally, we determined the 
amount of siRNA bound to the positively charged MCNPs at different concentrations using 
Picogreen assay (See supporting information, Figure S4).
Once we finished optimizing the synthesis of the MCNP constructs, we tested whether the 
MCNPs and/or the use of magnetically-facilitated delivery negatively affect the intrinsic 
ability of NSCs to proliferate and differentiate. To accomplish this, we assessed the 
proliferation and differentiation capabilities of the NSCs following their exposure to 
increasing concentrations of MCNPs (2~20 µg/mL) (See supporting information, Figure S5) 
that are complexed with negative control siRNA either in the presence or absence of an 
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external magnetic field (MF), using immunocytochemistry. Based on the expression of 
proliferation (Ki67) and differentiation (TUJ1 for neurons and GFAP for glial cells) 
markers, we were able to ascertain that the intrinsic biological functions of the NSCs were 
unaffected by our MCNPs and the delivery methods employed (Figure 3A). Since we 
confirmed the excellent biocompatibility and non-toxicity of our MCNPs in NSCs, we went 
ahead and tested the capability of these MCNPs to translocate genetic materials (siRNA or 
pDNA) into NSCs-GFP, which are genetically labeled with green fluorescent protein (GFP), 
in the presence or absence of an external MF and compared to commercially available 
transfection agents such as X-tremeGENE®. To this end, we first identified the optimal 
external MF exposure time that results in maximum transfection efficiency while preventing 
deleterious effects to cell viability (See supporting information, Figure S6). To accomplish 
this, we complexed the MCNPs with Cy3-labeled control siRNA (red color, Silencer®, 
Ambion) and incubated these complexes with NSCs-GFP in the presence of a MF for 
increasing periods of time (ranging from 0 to 6 h). After each exposure time point, the 
NSCs-GFP were washed with DPBS three times to remove untransfected MCNP-siRNA 
constructs. Using fluorescence microscopy, we observed a sharp increase in the uptake and 
localization of the tested MCNP-siRNA constructs (Figure 3B) into the cytoplasm of the 
NSCs-GFP after the complexes were incubated with the NSCs for only 30 min in the 
presence of a MF, as compared to control (Figure 3B). Upon increasing the time of 
incubation, we observed a minimal increase in the uptake and localization of MCNP-siRNA 
constructs See (supporting information, Figure S7). As such, we subsequently identified 30 
min as the optimum MF exposure time to offset any deleterious effects to the NSCs-GFP 
and used this for all of the following experiments.
Next, to demonstrate the delivery of functional MCNP-siRNA constructs, we chose siRNA 
against GFP (siGFP) and optimized the concentrations of MCNP and siGFP to be delivered 
by varying their respective concentrations and measuring the resulting GFP knockdown 
efficiency (See supporting information, Figure S8). Once we identified the optimum 
concentrations of MCNP (5 µg/ mL) and siGFP (200 nM), we compared the knockdown 
efficiency of MCNPs-based trasfection with that of the commercial transfection agent, X-
tremeGENE®. Specifically, the X-tremeGENE® was complexed with the same 
concentration of siRNA (200 nM) in the ratio of 3:1 as recommended by the manufacturer. 
To this end, the MCNP-siGFP and X-tremeGENE®-siGFP constructs were incubated with 
NSCs-GFP for increasing periods of time (from 15 min to 6 h), to first elucidate the 
correlation between the incubation time and the transfection efficiency, wherein we used the 
optimized MF exposure time (30 min) for all conditions. For comparison, we used the 
recommended incubation time (6 h) for the commercially available transfection reagents 
(e.g. X-tremeGENE®). After each period of incubation, the cells were washed with DPBS 
three times and further incubated for a period of 72 h, following which we quantified the 
decrease in the GFP signal intensity of the NSCs. We saw a significant difference in the 
gene silencing capability of MCNPs in the presence of a MF (55.45 % knockdown, p < 0.01) 
as compared to that in the absence of a MF (36.75% knockdown) (Figure 3C), when the 
complexes were incubated for 6 h. Additionally, upon comparison of our magnetically-
facilitated delivery with X-tremeGENE®-based delivery, we observed a remarkable 
difference in the time-dependent progression curve of the transfection efficiency (Figure 3D) 
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and in the cytotoxic effects exhibited by the two experimental conditions (See supporting 
information, Figure S9). In the case of magnetically-facilitated delivery (MCNP-siGFP/MF, 
Figure 3D), significantly higher levels of GFP knockdown (45.6% knockdown, p < 0.01) 
were observed after only 15 min of incubation with negligible cytotoxicity (~97% cell 
viability; See supporting information, Figure S9). Moreover, an additional increase in the 
gene silencing was seen after increasing the incubation time to 6h (55.45% knockdown). In 
contrast, negligible GFP knockdown was seen in the case of X-tremeGENE®-siGFP 
complexes after 15 min of incubation, which gradually increased upon increasing the 
incubation time, and reaches a plateau (38.95% knockdown, Figure 3D) after 6h, however, 
with significant cytotoxicity (60% cell viability; p < 0.01, See supporting information, 
Figure S9). From the analysis of the GFP knockdown results (Figure 3D), we identified 30 
min as the optimum incubation period needed to achieve significant downstream effects 
from gene delivery using MCNP/MF.
To see whether we could increase transfection efficiency further, we carried out repeated 
transfections of the same cell culture (a technique known as multifection[18]) using our 
MCNP/siGFP constructs and compared the gene-silencing efficiency achieved with 
multifection to that of a single transfection. We found that we were able to further improve 
the gene silencing efficiency from 55% (single transfection of MCNP/siGFP) to 65% 
(multifection of MCNP/siGFP) (See supporting information, Figure S10a). In the case of X-
tremeGENE multifection, we observed a similar trend of increased GFP knockdown (45% 
for multifection vs. 38% for single transfection). However, upon comparing their toxicity 
profiles, the viability of cells multi-transfected with MCNPs only decreased slightly (p > 
0.05 as compared to control), while that of X-tremeGENE resulted in significant cell death 
(p < 0.01 as compared to control, See supporting information, Figure S10b). Finally, besides 
siRNA, we also demonstrated the delivery of plasmid DNA (DsRED) to NSCs-GFP using 
our MCNPs under similar experimental conditions as compared to siRNA delivery. The 
magnetically-facilitated delivery of MCNP-DsRED complexes led to significantly higher 
levels of gene expression in NSCs within a shorter incubation time as compared to delivery 
of the same complexes in the absence of a MF (See supporting information, Figure S11). 
Thus, we observed that in spite of shorter-than commonly used incubation times, highly 
efficient gene deactivation (in the case of siGFP, Figure 3) or activation (in the case of 
DsRED; See supporting information, Figure S11) was achieved with negligible toxicity 
when magnetically-facilitated delivery of MCNP constructs was utilized, which is in 
contrast to that seen with the positive control experiments using standard transfection agents 
under the same conditions. However, to achieve comparable levels of knock-down results 
using the aforementioned lipid-based transfection methods, we typically needed longer 
incubation times (>6h), which can induce significant cytotoxic effects resulting in a low cell 
viability (~60% cell viability).
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Having demonstrated that our MCNPs, in the presence of a MF, can efficiently manipulate 
gene expression in NSCs without compromising their biological functions, we focused on 
controlling the neural differentiation of NSCs using our optimized conditions (Figure 4A) in 
order to demonstrate the utility of our MCNPs for stem cell-based therapies. For this 
demonstration, we selected functional siRNAs targeting key genes such as CAVEOLIN-1 
(siCAV)[19] or SOX9 (siSOX9)[20] (Figure 4A). These two genes (CAVEOLIN-1 and SOX9) 
have already been identified as “neural switches” that, when inhibited, selectively control 
the differentiation of NSCs into oligodendrocytes and neurons, respectively. To demonstrate 
the effective genetic manipulation of NSCs to control their differentiation, the MCNP-
siRNA complexes (MCNP, 5 µg/mL; siCAV/siSOX9, 200 nM) were prepared and incubated 
with NSCs in the presence of a MF (t = 30 min) as optimized previously. Untreated NSCs 
and NSCs treated with MCNP-siRNA constructs were characterized and quantified using 
immunocytochemistry by staining for oligodendrocytes [myelin binding protein (MBP)] and 
neuron [β-tubulin (TUJ1)] markers at day 7 after transfection (Figure 4B). From these 
experiments, we observed a significant increase in the percentage of oligodendrocytes 
(MBP-positive) and neurons (TUJ1-positive) in the cells treated with siCAV or siSOX9 
respectively, as compared to the spontaneous differentiation condition (Figure 4C, p < 0.01 
for siCAV and p < 0.001 for siSOX9 treatment). Thus, using the magnetically-facilitated 
delivery of MCNP-siRNA constructs, we were able to control the differentiation of NSCs to 
a particular lineage to a significantly greater extent and within shorter incubation periods, as 
compared to the untreated control NSCs. Finally, as this is the first report of using MCNPs 
to delivery genetic materials to NSCs, we investigated the cellular uptake mechanism of our 
magnetically-facilitated delivery of MCNPs into NSCs by treating the NSCs with 
endocytosis inhibitors and then quantifying their gene silencing effect. From this study, we 
were able to confirm that the cellular uptake occurred via a combination of clathrin-as well 
as caveolae-mediated endocytosis, which was similar to that of standard X-tremeGENE®-
based and MNP-based transfection (See supporting information, Figure S12).
Finally, to demonstrate the multifunctional advantages that a gold shell can have for MCNP-
based delivery of genetic materials and for stem cell-based therapies, we used dark imaging 
to confirm the uptake of the MCNPs into NSCs. As our MCNPs possess a thin gold shell 
and display surface plasmon resonance at 540 nm (Figure 2F), they can be used as cellular 
imaging modalities with simple dark-field microscopy. In particular, gold nanoparticles are 
known to scatter visible and infrared light owing to their localized surface plasmons.[21] In 
addition, they are significantly brighter than chemical fluorophores and do not photobleach, 
thus making them excellent candidates for biological imaging.[22] To this end, we studied 
the light scattering properties of our MCNPs complexed with control siRNA, by incubating 
them with NSCs and then monitored their intracellular uptake using a dark-field microscope. 
As seen in Figure 4D, the MCNPs scatter the incident white light more intensely as 
compared to the control cells. On the other hand, no noticeable change was seen when the 
cells were incubated with the magnetic core nanoparticles. Thus, besides improving the 
solubility and affording facile surface functionalization, the gold shell on our MCNPs can 
also be used as an imaging modality to confirm the localization of MCNPs to stem cells 
before further study or application. Also, owing to presence of the magnetic core, our 
MCNPs can afford MRI imaging capability as can be seen from Figure 4E providing further 
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advantages for in vivo applications.[8] To evaluate whether our MCNP retain their functions 
as an MRI contrast agent, we carried out MRI studies using MCNPs in phantom agar gels. 
Increasing the concentration of the MCNPs from 2 µg/ml to 50 µg/ml, led to a significant 
reduction in T2, as evident from the decreased signal intensity. Additionally, this decrease 
was comparable to that of just the core NPs indicating that the Au shell does not negatively 
affect the MRI contrast of the core. These results, thus demonstrate that our MCNPs could 
also function as an MRI contrast agent due to shortening of T2 relaxation and higher T2 
relaxivity.
In conclusion, we have synthesized magnetic core-shell nanoparticles (MCNPs) consisting 
of a highly magnetic ZnFe2O4 core surrounded by a gold outer-shell (ZnFe2O4@Au) and 
utilized them for the genetic manipulation of neural stem cells (NSCs) in a highly efficient, 
biocompatible, and spatiotemporally controlled manner. As a proof-of-concept for the utility 
of the MCNPS in the genetic manipulation of stem cells, we demonstrated that we could 
direct the differentiation of NSCs to specific lineages (neurons and oligodendrocytes) using 
our developed MCNPs to delivery siRNA. In particular, while MCNPs have been utilized 
for the highly efficient labeling of stem cells, this is the first demonstration that utilized 
MCNPs for the delivery of genetic materials (e.g. siRNA and pDNA) to stem cells. 
Moreover, these MCNPs hold a number of advantages for use with stem cell-based 
applications owing to multifunctionalities that result from the composite of the magnetic 
core with the gold outer-shell. In particular, we have demonstrated that the gold outer-shell 
i) enables a facile surface for the functionalization of our MCNPs with a cationic polyamine-
dendrimer thereby allowing for the complexation of the MCNs with negatively charged 
genetic materials, ii) enhances biocompatibility of the MCNP with stem cells, and iii) allows 
for the use of a simple method with which to confirm the presence of MCNPs within stem 
cells through dark field imaging. In addition, previous studies have shown that a gold outer-
shell improves aqueous solubility and long-term stability of the MCNPs. On the other hand, 
we have demonstrated that the magnetic core of the MCNP i) retains its excellent magnetic 
properties even after the formation of the gold outer-shell, ii) allows us to deliver 
nanoparticle-biomolecule constructs into the difficult-to-transfect stem cells with high 
transfection efficiency and with significantly shorter incubation times as compared to the 
conventional lipid-based transfection agents, and iii) can be used as an MRI contrast agent, 
which can be used in the future to track MCNP-transfected stem cells in vivo. Thus, MCNP-
based genetic manipulation method can potentially be a powerful tool for stem cell 
applications.
Experimental Section
All experimental details and protocols are provided in the Supporting Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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General schematic diagram of our NP synthesis and their application for the differentiation 
of stem cells. A) Schematic illustration of generating non-water-soluble MCNPs and 
watersoluble MCNPs.B) Magnetically-facilitated siRNA delivery using MCNPs to control 
the differentiation of stem cells.
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A)TEM image of the MCNPs. Scale bar = 10 nm, B) HRTEM image of a single MCNP. 
Scale bar = 5 nm, C) EDAX spectra of individual MCNPs, D) Representative picture 
depicting that the MCNPs dispersed in water are attracted to a magnet. E) Representative 
picture of non-water-soluble and water-soluble MCNPs in solution. Please note that the light 
pink color of watersoluble MCNPs indicates the formation of a gold shell. F) UV-Vis 
absorption spectra of the MCNP cores, non-water-soluble MCNPs and water-soluble 
MCNPs. The cores and non-water-soluble MCNPs were dissolved in chloroform before UV-
Vis analysis.
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A) Immunostaining data showing the proliferation (A1) and differentiation (A2) capability 
of NSCs after treatment with MCNPs (MCNPs, 5 µg/mL; negative control siRNA, 200 nM) 
in the presence of magnetic field (MF). The NSCs were stained with Ki67 as a proliferation 
marker and with TUJ1 (neurons) and GFAP (astrocytes) as differentiation markers. The 
nucleus was stained with Hoechst. B) Effect of presence (B1) and absence (B2) of MF on 
uptake of MCNP-Cy-3 labeled siRNA (MCNPs, 5 µg/mL; Cy-3 labeled siRNA, 200 nM) 
complexes in the NSCs. C) Knockdown of GFP fluorescence signal in NSCs treated with 
MCNPs-siGFP complexes in the presence (C1) or absence (C2) of an external magnetic 
field. The knockdown efficiency using MCNPs was compared to that using X-
TremeGENE® (C3) as a positive control. The concentrations of MCNPs and siGFP were 5 
µg/mL and 200 nM respectively. The amount of X-TremeGENE® used was within the 
manufacturer recommended range. The cells were exposed to the magnetic field for an 
optimum period of 30 min. D) Quantification of time-dependent GFP knockdown efficiency 
in NSCs using MCNPs [w/ or w/o magnetic field (MF)] and X-TremeGENE® complexed 
with either siGFP or control siRNA. As described in part C, the concentrations of MCNPs 
and siGFP were 5 µg/mL and 200 nM respectively.
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A)MCNP-mediated magnetically-facilitated delivery of siRNA against SOX9 (siSOX9) and 
CAVEOLIN-1 (siCAV) for inducing neural differentiation of NSCs. B) Fluorescence 
microscopy images depicting neuronal (top row) and oligodendrocyte differentiation 
(bottom row) of the NSCs following delivery of siSOX9 and siCAV respectively using 
MCNPs. The NSCs were stained with MBP (oligodendrocytes) and GFAP (astrocytes) in 
the case of MCNP/siCAV treated cells and for TUJ1 (neurons) and GFAP (astrocytes) in 
case of MCNP/siSOX9 treated cells on day 7 of transfection. The nucleus was stained with 
Hoechst. Scale bar is 1 µm C) Quantification of percent cells expressing neural markers 
when treated MCNP/siCAV and MCNP/siSOX9 as compared to untreated cells. All results 
represent the average mean of three independent experiments. Values are represented as 
mean ± SD.*denotes p <0.001 for neuronal differentiation and **denotes p< 0.01 for 
oligodendrocyte differentiation. D) Dark-field light scattering images for NSCs treated with 
MCNPs, Core (ZnFe2O4) MNPs and untreated NSCs (Control). Please note that the dark-
field scattering signals from the core MNP and control experiments come from background 
signal due to cellular components. Scale bar is 100 nm. E) Signal intensity T2 weighted MR 
images of MCNP and Core NPs in phantom agar gel at 2–50 µg/ml concentration at 25 °C.
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